Media coverage about RadNet (NASDAQ:RDNT) has been trending somewhat negative recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. RadNet earned a media sentiment score of -0.01 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 43.6474990568871 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of RadNet (RDNT) traded up 0.673% during trading on Thursday, reaching $11.225. The company had a trading volume of 121,638 shares. RadNet has a 12-month low of $5.25 and a 12-month high of $11.90. The company has a market cap of $530.56 million, a P/E ratio of 59.079 and a beta of 0.95. The firm has a 50-day moving average of $10.95 and a 200-day moving average of $8.10.
RadNet (NASDAQ:RDNT) last released its quarterly earnings data on Tuesday, August 8th. The medical research company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.07. RadNet had a net margin of 1.04% and a return on equity of 19.98%. The firm had revenue of $230.00 million for the quarter, compared to analyst estimates of $230.32 million. During the same period last year, the firm earned $0.09 earnings per share. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, equities research analysts anticipate that RadNet will post $0.30 EPS for the current year.
A number of brokerages have commented on RDNT. Zacks Investment Research cut RadNet from a “hold” rating to a “sell” rating in a research note on Tuesday. BidaskClub upgraded RadNet from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 24th. Jefferies Group LLC upgraded RadNet from a “hold” rating to a “buy” rating and boosted their price target for the stock from $7.00 to $12.00 in a research note on Tuesday, August 22nd. Finally, TheStreet upgraded RadNet from a “c” rating to a “b-” rating in a research note on Thursday, August 24th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $12.00.
TRADEMARK VIOLATION NOTICE: “Somewhat Negative News Coverage Somewhat Unlikely to Affect RadNet (RDNT) Share Price” was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://transcriptdaily.com/2017/10/12/somewhat-negative-news-coverage-somewhat-unlikely-to-affect-radnet-rdnt-share-price.html.
In related news, Director David L. Swartz sold 25,000 shares of the firm’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $10.98, for a total transaction of $274,500.00. Following the completion of the sale, the director now owns 274,108 shares in the company, valued at $3,009,705.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Sandy Nyholm Kaminsky sold 1,100,000 shares of the firm’s stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $10.95, for a total transaction of $12,045,000.00. The disclosure for this sale can be found here. Insiders have sold 1,236,900 shares of company stock worth $13,452,504 over the last three months. 9.36% of the stock is owned by insiders.
RadNet Company Profile
RadNet, Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island.
Receive News & Ratings for RadNet Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet Inc. and related companies with MarketBeat.com's FREE daily email newsletter.